Core Viewpoint - Yao Jinbo, a pioneer in the internet industry, has become the new actual controller of A-share company Yiming Pharmaceutical (002826.SZ) by investing 6.62 billion yuan, leading to a significant surge in the company's stock price with three consecutive trading limits reached [3][5][6]. Group 1: Investment and Acquisition Details - Yao Jinbo's acquisition of Yiming Pharmaceutical marks his debut in the A-share market, with the stock price rising due to his involvement [3][5]. - The acquisition involved a share transfer agreement where Beijing Fuhai, owned by Yao and his wife, purchased 23% of the company's shares at a price of 15.10 yuan per share, representing a 24% premium over the last closing price before suspension [6][7]. - Yao Jinbo's investment strategy includes a commitment from the previous controller, Gao Fan, to ensure that Yiming Pharmaceutical's revenue remains above 6 billion yuan and net profit above 300 million yuan from 2025 to 2027 [7][8]. Group 2: Company Performance and Market Position - Yiming Pharmaceutical has shown stable but modest performance, with revenues around 700 million yuan and net profits fluctuating around 40 million yuan from 2020 to 2024 [9]. - The company's main product, Miglitol tablets, accounted for 72.72% of its revenue in 2024, while other products, such as the Gua Lou Pi injection, have seen significant declines in revenue [9][10]. - The company has terminated its collaboration with Shanghai Pharmaceuticals regarding the Gua Lou Pi injection, indicating potential shifts in its product strategy [10]. Group 3: Market Speculation and Future Prospects - There is speculation that Yao Jinbo may consider a reverse merger to list 58 Group's assets through Yiming Pharmaceutical, as the latter is viewed as a valuable shell resource [4][18]. - Yao's previous ventures, including 58.com, have faced challenges in the competitive landscape, with various assets underperforming, raising questions about the viability of injecting these assets into Yiming Pharmaceutical [21][23]. - The competitive pressures from companies like BOSS Zhipin, Meituan, and JD.com are significant, and Yao Jinbo must optimize his assets to regain market competitiveness [26][25].

Core Viewpoint - The control transfer of Yiming Pharmaceutical has been completed, with the new owner being Yao Jinbo, the founder of 58.com, marking it as his first A-share listed company [2][3]. Group 1: Company Overview - Yiming Pharmaceutical, with a market value of just over 2 billion, has been relatively unnoticed until now [2]. - The company was listed at the end of 2016, focusing on chronic medications for diabetes and cardiovascular diseases, including products like Yiming Aotianping and Yiming Weidongling [3]. Group 2: Financial Performance - Yiming Pharmaceutical's revenue has stagnated, with 2020 revenue at 600 million and projected revenue of 650 million in 2024, showing a decline of 7.4% in Q1 2025 [3][5]. - The net profit has remained stable at around 30-40 million, with R&D expenses projected to be over 15 million in 2024, indicating limited growth potential for a pharmaceutical company [5]. Group 3: Acquisition Insights - Yao Jinbo's acquisition price of 15.10 CNY per share represents a 24% premium over the last closing price and a 30% premium over the 20-day average price prior to suspension, indicating a strong commitment [2]. - The financials reveal that Yiming Pharmaceutical has a clean balance sheet, with 320 million in cash, 170 million in accounts receivable, and total liabilities under 300 million, suggesting it is a clean shell for potential future operations [6][9]. Group 4: Future Expectations - The share transfer agreement includes performance commitments from the previous controlling shareholder, ensuring revenue of no less than 600 million and net profit of no less than 30 million from 2025 to 2027, which may guide Yao's future plans for the company [11].